Actively Recruiting
Characterizing Long-Term Safety and Use of Eplontersen in Transthyretin Amyloidosis Patients with Liver Transplant or Severe Hepatic Impairment
Led by AstraZeneca · Updated on 2026-09-14
320
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an observational cohort study to understand how eplontersen is used in patients with transthyretin amyloidosis ATTR, including those who have had a liver transplant or have severe liver impairment. The study aims to fill gaps in knowledge about these patient groups and to assess the long-term safety of eplontersen among all new users. It includes adults aged 18 and older with a confirmed ATTR diagnosis. The study collects data from participants who started eplontersen treatment within one year before joining the study, as well as comparative data from patients who started other ATTR treatments but have not used eplontersen. Data collection will begin in the third quarter of 2026 and continue until the first quarter of 2032, with annual interim reports and a final report in early 2033. There is no active treatment given as part of this study since it is observational. Participants provide data through the study observation period, which monitors demographic and clinical characteristics, liver transplant history, and severe hepatic impairment prevalence. Researchers track long-term safety by recording new clinical events, abnormal lab results, and serious adverse events. Safety events are monitored closely and analyzed over specific time intervals throughout the study duration, which lasts about five and a half years.
CONDITIONS
Brief Title
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here